Αρχική World News Neoadjuvant Serplulimab with S-1 Plus Oxaliplatin Followed by Adjuvant Serplulimab Significantly Improves... World News Neoadjuvant Serplulimab with S-1 Plus Oxaliplatin Followed by Adjuvant Serplulimab Significantly Improves EFS in PD-L1-positive, Resectable Gastric or GEJ Adenocarcinoma Από Ogkologos - 30 Ιουνίου, 2026 218 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASTRUM-006 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Addressing Cancer Disparities and New Research in Treating HPV-Positive Head and... 31 Μαρτίου, 2022 Moving target – retrotransposable elements and cancer 11 Ιουλίου, 2023 EMA Recommends Granting a Marketing Authorisation for Phesgo (Pertuzumab / Trastuzumab) 19 Νοεμβρίου, 2020 How We’re Working to Build a Cancer Survivorship Community: Survivors’ Perspectives 14 Δεκεμβρίου, 2023 Φόρτωση περισσοτέρων HOT NEWS Ahead of ESMO Immuno-Oncology Congress 2025: topics at a glance On legacy giving: “It allows me to give something more meaningful... Test Detects Early Signs of Remaining Cancer in Kids Treated for... EMA Recommends Extension of Therapeutic Indications for Tisagenlecleucel